Protalix BioTherapeutics, Inc. Cash Flow Statement
PLX|14 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 14 fiscal years. All figures from audited SEC 10-K filings.
Protalix BioTherapeutics, Inc. used $1M in operating cash flow and negative free cash flow of $2M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $8.3M | -$14.9M | -$27.6M | -$6.5M | -$18.3M | -$26.5M | -$83.4M | $58.0M | -$29.9M | -$27.8M | -$11.6M | -$36.5M | -$29.0M | -$31.4M |
| Depreciation & Amortization | $1.2M | $1.1M | $1.1M | $1.3M | $1.6M | $1.7M | $1.9M | $2.4M | $3.1M | $3.5M | $3.7M | - | - | - |
| Operating Cash Flow | -$1.3M | -$25.0M | -$10.3M | -$26.1M | -$19.4M | -$7.7M | -$10.0M | -$24.3M | -$29.3M | -$30.7M | $635.0K | -$23.6M | -$38.5M | $44.5M |
| Capital Expenditures | $1.1M | $628.0K | $1.5M | $655.0K | $627.0K | $686.0K | $971.0K | $464.0K | $785.0K | $1.9M | $2.1M | $5.7M | $7.9M | $6.2M |
| Free Cash Flow | -$2.5M | -$25.6M | -$11.7M | -$26.8M | -$20.0M | -$8.4M | -$11.0M | -$24.7M | -$30.1M | -$32.5M | -$1.4M | -$29.3M | -$46.3M | $38.3M |
| FCF Margin | -3.8% | -53.8% | -30.6% | -42.5% | -36.5% | -24.6% | -52.0% | -567.1% | -853.4% | - | -4.1% | -349.1% | -697.4% | 9860.0% |